GUILLERMINA NELSON: Open Payments
NPI 1326417106 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$476 in 20 payments from 10 companies in 2025. Trend: 2023 $69 · 2024 $263 · 2025 $476
Food & beverage: $476
| Company | Payments | Amount |
|---|---|---|
| ARGENX US, INC. | 5 | $112 |
| ABBVIE INC. | 5 | $106 |
| Merz Pharmaceuticals, LLC | 2 | $57 |
| Neurelis, Inc. | 2 | $46 |
| Genentech USA, Inc. | 1 | $34 |
| E.R. Squibb & Sons, L.L.C. | 1 | $30 |
| Alexion Pharmaceuticals, Inc. | 1 | $28 |
| CATALYST PHARMACEUTICALS, INC. | 1 | $25 |
| Janssen Biotech, Inc. | 1 | $21 |
| UCB, Inc. | 1 | $18 |
Products named: VYVGART HYTRULO, Xeomin, UBRELVY, VALTOCO, Ocrevus Zunovo, ZEPOSIA, BOTOX, ULTOMIRIS.
Industry payments across TX — which companies pay providers there.
